You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDonepezil
Accession NumberDB00843  (APRD00039)
TypeSmall Molecule
GroupsApproved
Description

Donepezil (Aricept), is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer’s disease where it is used to increase cortical acetylcholine. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, donepezil’s effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. Donepezil has been tested in other cognitive disorders including Lewy body dementia and Vascular dementia, but it is not currently approved for these indications. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome.

Structure
Thumb
Synonyms
SynonymLanguageCode
DomepezilNot AvailableIS
DonepezilGermanINN
DonepezilFrenchINN
DonepeziloSpanishINN
DonepezilumLatinINN
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Donepezil Hydrochloridetablet, film coated5 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs1996-11-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs1996-11-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricepttablet, film coated5 mgoralPhysicians Total Care, Inc.2008-05-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricepttablet, film coated10 mgoralPhysicians Total Care, Inc.2005-05-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralCardinal Health1996-11-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricepttablet, film coated5 mgoralCardinal Health1996-11-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricepttablet, film coated10 mgoralCardinal Health1996-11-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricepttablet, film coated10 mgoralPd Rx Pharmaceuticals, Inc.1996-11-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralGreenstone LLC1996-11-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralGreenstone LLC1996-11-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricepttablet, film coated5 mgoralEisai Inc.1996-11-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricepttablet, film coated10 mgoralEisai Inc.1996-11-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricepttablet, film coated23 mgoralEisai Inc.2010-07-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricept ODTtablet, orally disintegrating5 mgoralEisai Inc.2004-10-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricept ODTtablet, orally disintegrating10 mgoralEisai Inc.2004-10-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricepttablet, film coated10 mgoralbryant ranch prepack1996-11-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralContract Pharmacy Services Pa2011-01-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralContract Pharmacy Services Pa2011-01-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aricepttablet5 mgoralPfizer Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Aricepttablet10 mgoralPfizer Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Donepezil Hydrochloridetablet, film coated5 mgoralTeva Pharmaceuticals USA Inc2011-05-312015-10-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralTeva Pharmaceuticals USA Inc2011-05-312015-07-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralWest ward Pharmaceutical Corp2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralWest ward Pharmaceutical Corp2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralMylan Pharmaceuticals Inc.2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralMylan Pharmaceuticals Inc.2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet5 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet5 mgoralSandoz Inc2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet10 mgoralSandoz Inc2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, orally disintegrating5 mgoralSandoz Inc2011-05-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, orally disintegrating10 mgoralSandoz Inc2011-05-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralMajor Pharmaceuticals2011-06-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralMajor Pharmaceuticals2011-06-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralMajor Pharmaceuticals2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralMajor Pharmaceuticals2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralTorrent Pharmaceuticals Limited2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralTorrent Pharmaceuticals Limited2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralAccord Healthcare, Inc.2011-12-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralAccord Healthcare, Inc.2011-12-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralINDICUS PHARMA LLC2011-06-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralINDICUS PHARMA LLC2011-06-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepeziltablet5 mgoralCamber Pharmaceuticals, Inc.2015-02-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepeziltablet10 mgoralCamber Pharmaceuticals, Inc.2015-02-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralAidarex Pharmaceuticals LLC2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralMacleods Pharmaceuticals Limited2012-08-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralMacleods Pharmaceuticals Limited2012-08-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, orally disintegrating5 mgoralMacleods Pharmaceuticals Limited2012-12-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, orally disintegrating10 mgoralMacleods Pharmaceuticals Limited2012-12-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated23 mgoralMacleods Pharmaceuticals Limited2014-01-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralRebel Distributors Corp2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralVensun Pharmaceuticals, Inc.2014-12-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralVensun Pharmaceuticals, Inc.2014-12-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralPd Rx Pharmaceuticals, Inc.2011-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralSolco Healthcare US, LLC2011-11-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralSolco Healthcare US, LLC2011-11-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralActavis Inc.2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet23 mgoralPar Pharmaceutical, Inc.2013-09-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralScie Gen Pharmaceuticals, Inc.2014-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralScie Gen Pharmaceuticals, Inc.2014-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralUnit Dose Services2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralUnit Dose Services2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralREMEDYREPACK INC.2013-05-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralREMEDYREPACK INC.2013-05-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralREMEDYREPACK INC.2013-07-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralPhysicians Total Care, Inc.2010-12-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralPhysicians Total Care, Inc.2010-12-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated23 mgoralDr. Reddys Laboratories Limited2013-07-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralDr. Reddys Laboratories Limited2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralDr. Reddys Laboratories Limited2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralCardinal Health2011-11-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralCardinal Health2011-06-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralCardinal Health2011-06-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralCardinal Health2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralWockhardt Limited2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralWockhardt Limited2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralHikma Pharmaceutical2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralHikma Pharmaceutical2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralJubilant Cadista Pharmaceuticals Inc.2011-05-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralJubilant Cadista Pharmaceuticals Inc.2011-05-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralGolden State Medical Supply, Inc2014-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralGolden State Medical Supply, Inc2014-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralSt Marys Medical Park Pharmacy2014-05-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralSt Marys Medical Park Pharmacy2014-05-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralREMEDYREPACK INC.2014-12-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralSun Pharmaceutical Industries Limited2011-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralSun Pharmaceutical Industries Limited2011-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralRanbaxy Pharmaceuticals Inc.2010-11-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralRanbaxy Pharmaceuticals Inc.2010-11-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralbryant ranch prepack2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet5 mgoralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, orally disintegrating5 mgoralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-03-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, orally disintegrating10 mgoralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-03-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-03-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-03-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet10 mgoralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralWockhardt USA LLC.2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralWockhardt USA LLC.2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, orally disintegrating5 mgoralCadila Healthcare Limited2011-05-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, orally disintegrating10 mgoralCadila Healthcare Limited2011-05-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralCadila Healthcare Limited2011-05-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralCadila Healthcare Limited2011-05-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralAurobindo Pharma Limited2013-09-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralAurobindo Pharma Limited2013-09-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralContract Pharmacy Services Pa2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralContract Pharmacy Services Pa2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralAmerican Health Packaging2011-03-012015-07-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralAmerican Health Packaging2011-03-012015-02-28Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralAmerican Health Packaging2014-06-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralAmerican Health Packaging2014-06-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralCarilion Materials Management2011-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralZydus Pharmaceuticals (USA) Inc.2011-05-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralZydus Pharmaceuticals (USA) Inc.2011-05-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, orally disintegrating5 mgoralZydus Pharmaceuticals (USA) Inc.2011-05-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, orally disintegrating10 mgoralZydus Pharmaceuticals (USA) Inc.2011-05-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralPreferred Pharmaceuticals, Inc.2011-05-312015-10-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated5 mgoralMc Kesson Contract Packaging2013-04-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepezil Hydrochloridetablet, film coated10 mgoralMc Kesson Contract Packaging2013-04-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Donepeziltablet5 mgoralPro Doc LimiteeNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Donepeziltablet10 mgoralPro Doc LimiteeNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Donepeziltablet5 mgoralSivem Pharmaceuticals UlcNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Donepeziltablet10 mgoralSivem Pharmaceuticals UlcNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Over the Counter ProductsNot Available
International Brands
NameCompany
AlzepilEgis
DaviaTerapia
DepzilPsyco Remedies
DoneceptActavis
DonecilABL Pharma
DonepAlkem
DonepexSchafer
DonesynSynthon
DopezilMedis
EranzWyeth
Memac Pfizer
Nomi-NoxJohnson
PezaleSandoz
RedumasTeva
ZolpezilActavis
Brand mixtures
Brand NameIngredients
Carrier PlusDonepezil and Memantine
Salts
Name/CASStructureProperties
Donepezil hydrochloride
ThumbNot applicableDBSALT000938
CategoriesNot Available
CAS number120014-06-4
WeightAverage: 379.492
Monoisotopic: 379.214743799
Chemical FormulaC24H29NO3
InChI KeyADEBPBSSDYVVLD-UHFFFAOYSA-N
InChI
InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3
IUPAC Name
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one
SMILES
COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassBenzylpiperidines
Direct ParentN-benzylpiperidines
Alternative Parents
Substituents
  • N-benzylpiperidine
  • Indanone
  • Indane
  • Aryl alkyl ketone
  • Aryl ketone
  • Phenylmethylamine
  • Benzylamine
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the palliative treatment of mild to moderate dementia of the Alzheimer's type.
PharmacodynamicsDonepezil is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, donepezil's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that donepezil alters the course of the underlying dementing process.
Mechanism of actionDonepezil is a piperidine derivative that is a centerally active, reversible inhibitor of acetylcholinesterase. This drug is structurally unrelated to other anticholinesterase agents. Donepezil's proposed mechanism of action involves the reversible inhibition of cholinesterases (eg. acetylcholinesterase), which prevents the hydrolysis of acetycholine, and leads to an increased concentration of acetylcholine at cholinergic synapses. Evidence suggests that the anticholinesterase activity of donepezil is relatively specific for acetylcholinesterase in the brain.
AbsorptionDonepezil is well absorbed with a relative oral bioavailability of 100% and reaches peak plasma concentrations in 3 to 4 hours.
Volume of distribution
  • 12 L/kg
Protein binding96%
Metabolism

Donepezil is metabolized by CYP 450 isoenzymes 2D6 and 3A4 in the liver and also undergoes glucuronidation. The main metabolite, 6-O-desmethyl donepezil, has been reported to inhibit AChE to the same extent as donepezil in vitro.

SubstrateEnzymesProduct
Donepezil
5-O-DesmethyldonepezilDetails
Donepezil
6-O-DesmethyldonepezilDetails
Donepezil
Donepezil metabolite M4Details
Donepezil
Not Available
Donepezil metabolite M3Details
Donepezil
Not Available
Donepezil metabolite M5Details
Donepezil
Not Available
Donepezil metabolite M6Details
Donepezil metabolite M3
Not Available
Donepezil metabolite M7Details
Donepezil metabolite M7
Not Available
Donepezil metabolite M7 sulfateDetails
Donepezil metabolite M4
Not Available
Donepezil metabolite M8Details
5-O-Desmethyldonepezil
Not Available
Donepezil metabolite M9Details
6-O-Desmethyldonepezil
Not Available
Donepezil metabolite M9Details
Donepezil metabolite M9
Not Available
Donepezil metabolite M10Details
5-O-Desmethyldonepezil
Not Available
Donepezil metabolite M7Details
Donepezil metabolite M7
Not Available
Donepezil metabolite M10Details
6-O-Desmethyldonepezil
Not Available
Donepezil metabolite M11Details
5-O-Desmethyldonepezil
Not Available
Donepezil metabolite M12Details
Donepezil metabolite M9
Not Available
Donepezil metabolite M13Details
Donepezil metabolite M9
Not Available
Donepezil metabolite M14Details
Route of eliminationDonepezil is both excreted in the urine intact and extensively metabolized to four major metabolites, two of which are known to be active, and a number of minor metabolites, not all of which have been identified.
Half life70 hours
Clearance
  • apparent plasma cl=0.13 L/hr/kg
ToxicitySymptoms of overdose include severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9953
Caco-2 permeable+0.7742
P-glycoprotein substrateSubstrate0.7721
P-glycoprotein inhibitor IInhibitor0.7641
P-glycoprotein inhibitor IIInhibitor0.8202
Renal organic cation transporterInhibitor0.7696
CYP450 2C9 substrateNon-substrate0.8465
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7202
CYP450 1A2 substrateInhibitor0.5072
CYP450 2C9 substrateNon-inhibitor0.8189
CYP450 2D6 substrateInhibitor0.8684
CYP450 2C19 substrateNon-inhibitor0.8356
CYP450 3A4 substrateNon-inhibitor0.7411
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6138
Ames testNon AMES toxic0.6441
CarcinogenicityNon-carcinogens0.9528
BiodegradationNot ready biodegradable0.9145
Rat acute toxicity3.0123 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5386
hERG inhibition (predictor II)Inhibitor0.8095
Pharmacoeconomics
Manufacturers
  • Eisai inc
  • Mutual pharmaceutical co inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tabletoral23 mg
Tabletoral5 mg
Tablet, film coatedoral10 mg
Tablet, film coatedoral23 mg
Tablet, film coatedoral5 mg
Tablet, orally disintegratingoral10 mg
Tablet, orally disintegratingoral5 mg
Prices
Unit descriptionCostUnit
Aricept ODT 30 5 mg Dispersible Tablet Box272.99USD box
Aricept 10 mg tablet10.93USD tablet
Aricept 5 mg tablet9.78USD tablet
Aricept odt 10 mg tablet8.03USD tablet
Aricept odt 5 mg tablet8.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada13388081996-12-242013-12-24
Canada22528062005-11-222017-06-06
United States48958411993-11-252010-11-25
United States77275482002-06-232022-06-23
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point206.72 °CNot Available
water solubility2.931 mg/LNot Available
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0045 mg/mLALOGPS
logP4.14ALOGPS
logP4.21ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)17.02ChemAxon
pKa (Strongest Basic)8.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity112.11 m3·mol-1ChemAxon
Polarizability44.34 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Akio Imai, Hideaki Watanabe, Takashi Kajima, Yasushi Ishihama, Akiyo Ohtsuka, Tomohide Tanaka, Yukio Narabu, “Polymorphs of donepezil hydrochloride and process for production.” U.S. Patent US5985864, issued December, 1988.

US5985864
General Reference
  1. Xiong G, Doraiswamy PM: Combination drug therapy for Alzheimer’s disease: what is evidence-based, and what is not? Geriatrics. 2005 Jun;60(6):22-6. Pubmed
  2. Yesavage JA, Mumenthaler MS, Taylor JL, Friedman L, O’Hara R, Sheikh J, Tinklenberg J, Whitehouse PJ: Donepezil and flight simulator performance: effects on retention of complex skills. Neurology. 2002 Jul 9;59(1):123-5. Pubmed
  3. Sugimoto H: Donepezil hydrochloride: a treatment drug for Alzheimer’s disease. Chem Rec. 2001;1(1):63-73. Pubmed
External Links
ATC CodesN06DA02
AHFS Codes
  • 12:04.00
PDB Entries
FDA labelDownload (303 KB)
MSDSDownload (58.2 KB)
Interactions
Drug Interactions
Drug
AcepromazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
AcetophenazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
AcetylcholineAcetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.
AmisulprideAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
AripiprazoleAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
BenzquinamideAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
BretyliumMay enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.
CarbacholAcetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.
CarphenazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ChlormezanoneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ChlorpromazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ChlorprothixeneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ClozapineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
DipyridamoleMay diminish the therapeutic effect of Acetylcholinesterase Inhibitors.
DroperidolAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
FencamfamineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
FlupentixolAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
FluphenazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
FluspirileneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
HaloperidolAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
LacosamideBradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.
LoxapineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
MesoridazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
MethotrimeprazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
MolindoneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
OlanzapineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
OndansetronAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
PaliperidoneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
PerphenazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
PimozideAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
PiperacetazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ProchlorperazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
PromazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
QuetiapineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
RemoxiprideAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ReserpineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
RisperidoneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
RuxolitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
SertindoleAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
SuccinylcholineAcetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.
SulpirideAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ThioridazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ThiothixeneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
TofacitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
TrifluoperazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
TriflupromazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ZiprasidoneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ZuclopenthixolAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

1. Acetylcholinesterase

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Acetylcholinesterase P22303 Details

References:

  1. Davis KL: Alzheimer’s disease: seeking new ways to preserve brain function. Interview by Alice V. Luddington. Geriatrics. 1999 Feb;54(2):42-7; quiz 48. Pubmed
  2. Kryger G, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure. 1999 Mar 15;7(3):297-307. Pubmed
  3. Shepherd G, Klein-Schwartz W, Edwards R: Donepezil overdose: a tenfold dosing error. Ann Pharmacother. 1999 Jul-Aug;33(7-8):812-5. Pubmed
  4. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y: Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol. 1999 Sep 10;380(2-3):101-7. Pubmed
  5. Jann MW: Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy. 2000 Jan;20(1):1-12. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  7. Sugimoto H: Donepezil hydrochloride: a treatment drug for Alzheimer’s disease. Chem Rec. 2001;1(1):63-73. Pubmed
  8. Ki YS, Park EY, Lee HW, Oh MS, Cho YW, Kwon YK, Moon JH, Lee KT: Donepezil, a potent acetylcholinesterase inhibitor, induces caspase-dependent apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull. 2010;33(6):1054-9. Pubmed
  9. Repantis D, Laisney O, Heuser I: Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010 Jun;61(6):473-81. Epub 2010 Mar 1. Pubmed

2. 5-hydroxytryptamine receptor 2A

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: other/unknown

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2A P28223 Details

References:

  1. Hayslett RL, Tizabi Y: Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette’s syndrome. Pharmacol Biochem Behav. 2005 Aug;81(4):879-86. Pubmed
  2. Hayslett RL, Tizabi Y: Effects of donepezil on DOI-induced head twitch response in mice: implications for Tourette syndrome. Pharmacol Biochem Behav. 2003 Dec;76(3-4):409-15. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12